It's almost that time of year again: the holiday season. Since the boy was born the holidays have?taken on new meaning. We now have the joy of looking at the season through the eyes of a child and that reminds of of why we like cold-as-heck November and December in the first place. What's more, [...]
As advanced prostate cancer progresses it becomes inevitable that we will develop bone metastases. The treatments available are designed to slow disease progression, to relieve pain and to avoid the complications that result from bones being weakened by the cancer. Weakened bones become very susceptible to fractures, with prostate cancer the most likely sight for [...]
U.S. News and World Review, in their HealthDay section reported an interesting aspect of the continuing debate about treatment vs. “watchful waiting” (active surveillance). The article, written by Karen Pallarito “Rethinking Prostate Cancer in Older Men” suggests aggressive treatment is viable, even for patients in their late 70s! Her premise, that increasing life expectancies, improved [...]
The number of men with Hormone Refractory Prostate Cancer (HRCP) is ever increasing; some statisticians feel that it could eventually become the most common cancer in the male population. The clinical variability, the lack of consensus on patients' eligibility for starting a different treatment, and the response criteria seen in literature have made it difficult [...]
According to data published in the Journal of Clinical Oncology (2008; 26:4426-34), once a week, bisphosphonate therapy improves bone density and improves turnover in prostate cancer patients with nonmetastatic disease who are on androgen deprivation therapy (ADT). A second year of bisphosphonate therapy provides additional skeletal benefit, whereas discontinuation results in bone loss and increased [...]